MedPath
Found 549574 clinical trials
Sort by:

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

Not Applicable
Not yet recruiting
Conditions
Colorectal Cancer
Interventions
Drug: Bevacizumab,Irinotecan liposome (II),5-FU/LV
First Posted Date
2025-08-14
Last Posted Date
2025-08-14
Lead Sponsor
Sanjun Cai
Target Recruit Count
300
Registration Number
NCT07123441
Locations
🇨🇳

Fudan University, Cancer Hospital, Shanghai, Shanghai, China

Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment

Not Applicable
Recruiting
Conditions
Helicobacter Pylori
Interventions
Drug: Keverprazan 10 days
Drug: Keverprazan 14 days
First Posted Date
2025-08-14
Last Posted Date
2025-08-14
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
414
Registration Number
NCT07122024
Locations
🇨🇳

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

AI for Detection of Brain Aneurysm: Low-cost Opportunistic Screening

Not Applicable
Not yet recruiting
Conditions
Intracranial Aneurysm
First Posted Date
2025-08-14
Last Posted Date
2025-08-14
Lead Sponsor
Ziekenhuis Oost-Limburg
Target Recruit Count
10000
Registration Number
NCT07123818

Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy

Not yet recruiting
Conditions
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Guillain-Barré Syndrome (GBS)
First Posted Date
2025-08-14
Last Posted Date
2025-08-14
Lead Sponsor
University of Erlangen-Nürnberg Medical School
Target Recruit Count
30
Registration Number
NCT07121985

Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease

Not Applicable
Recruiting
Conditions
Mild to Severe Crohns Disease
First Posted Date
2025-08-14
Last Posted Date
2025-08-14
Lead Sponsor
The Third Xiangya Hospital of Central South University
Target Recruit Count
24
Registration Number
NCT07123207
Locations
🇨🇳

The Third Xiangya Hospital of Central South University, Changsha, Hunan, China

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not Applicable
Not yet recruiting
Conditions
Relapsed and Refractory DLBCL
Interventions
First Posted Date
2025-08-14
Last Posted Date
2025-08-14
Lead Sponsor
Ruijin Hospital
Target Recruit Count
22
Registration Number
NCT07122609
Locations
🇨🇳

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Neural Contributions to Exercise-Induced Hypoalgesia With Blood Flow Restriction

Not Applicable
Recruiting
Conditions
Healthy
First Posted Date
2025-08-14
Last Posted Date
2025-08-14
Lead Sponsor
University of Gran Rosario
Target Recruit Count
20
Registration Number
NCT07122011
Locations
🇦🇷

University Center for Assistance, Teaching and Research (CUADI), Rosario, Santa Fe, Argentina

A Five-Day Contagious Laughter Intervention for Adult Well-being

Not Applicable
Completed
Conditions
Well-being
First Posted Date
2025-08-14
Last Posted Date
2025-08-14
Lead Sponsor
Zayed University
Target Recruit Count
100
Registration Number
NCT07123571
Locations
🇦🇪

Zayed University, Abu Dhabi, United Arab Emirates

Study of Acquired Resistance to Alkylator Chemotherapy in Endocrine Neoplasms

Recruiting
Conditions
Neuroendocrine (NE) Tumors
Endocrine Cancer
First Posted Date
2025-08-14
Last Posted Date
2025-08-14
Lead Sponsor
Uppsala University
Target Recruit Count
94
Registration Number
NCT07121998
Locations
🇸🇪

Akademiska Sjukhuset, Uppsala, Sweden

Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors

Not Applicable
Not yet recruiting
Conditions
Recurrent or Metastatic Solid Tumors With Positive ALPP
Interventions
Biological: Anti ALPP CAR-T cells treatment
First Posted Date
2025-08-14
Last Posted Date
2025-08-14
Lead Sponsor
Haifeng Qin
Target Recruit Count
24
Registration Number
NCT07123493
Locations
🇨🇳

Beijing GoBroad Hospital, Beijing, Beijing, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.